# Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

Study · id `cardio:ct-nct02752113` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02752113](<https://clinicaltrials.gov/study/NCT02752113>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02752113

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

## Technical summary

Registry record NCT02752113. Randomized; no masking; primary purpose treatment. Start 2016-04 (actual); primary completion 2018-11-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 101 participants (enrolled count; ClinicalTrials.gov record NCT02752113, source copy `cardio:ctgov-nct02752113-2019-07-29`, retrieved 2026-10-26)
- Started: 2016-04 (actual) (ClinicalTrials.gov record NCT02752113, source copy `cardio:ctgov-nct02752113-2019-07-29`, retrieved 2026-10-26)
- Primary completion: 2018-11-07 (actual) (ClinicalTrials.gov record NCT02752113, source copy `cardio:ctgov-nct02752113-2019-07-29`, retrieved 2026-10-26)
- Completion: 2019-05 (actual) (ClinicalTrials.gov record NCT02752113, source copy `cardio:ctgov-nct02752113-2019-07-29`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT02752113, source copy `cardio:ctgov-nct02752113-2019-07-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02752113-2019-07-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes
- Acronym: ELMI
- Condition: Diabetes Mellitus Type 2
- Intervention (Drug): Empagliflozin and Linagliptin
- Intervention (Drug): Metformin and Insulin sc
- Lead sponsor: Institut für Pharmakologie und Präventive Medizin
- Lead sponsor class: NETWORK
- Collaborator: University of Erlangen-Nürnberg Medical School
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: University of Erlangen-Nürnberg Medical School (`cardio:org-university-of-erlangen-nurnberg-medical-school`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes (`cardio:pubmed-31816038`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine (`cardio:pubmed-34481498`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Is GFR decline induced by SGLT2 inhibitor of clinical importance? (`cardio:pubmed-38811998`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1a56f6388ae63292b776f059be8f6a9964c184d64ef9617f03753a7b2ff5025c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
